Author:
Motzer Robert J.,Russo Paul,Haas Naomi,Doehn Christian,Donskov Frede,Gross-Goupil Marine,Varlamov Sergei,Kopyltsov Evgeny,Lee Jae Lyun,Lim Ho Yeong,Melichar Bohuslav,Zemanova Milada,Rini Brian,Choueiri Toni K.,Wood Lori,Reaume M. Neil,Stenzl Arnulf,Chowdhury Simon,McDermott Ray,Michael Agnieszka,Izquierdo Miguel,Aimone Paola,Zhang Hong,Sternberg Cora N.
Funder
Novartis Pharmaceuticals Corporation
Memorial Sloan-Kettering Cancer Center
Reference9 articles.
1. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial;Haas;Lancet,2016
2. Adjuvant treatment for high-risk clear cell renal cancer: updated results of a high-risk subset of the ASSURE randomized trial;Haas;JAMA Oncol,2017
3. Primary efficacy analysis results from the SORCE trial (RE05): adjuvant sorafenib for renal cell carcinoma at intermediate or high risk of relapse: an international, randomised double-blind phase III trial led by the MRC CTU at UCL;Eisen;Ann Oncol,2019
4. Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial;Gross-Goupil;Ann Oncol,2018
5. Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy;Ravaud;N Engl J Med,2016
Cited by
47 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献